Whether STK36 is a good candidate target in clinical trials and can be used as an adjuvant for the treatment of docetaxel resistant prostate cancer with docetaxel requires further in vivo confirmation, which is also our next research direction. This evidence concerns the gene STK36 and prostate cancer.